FDA cleared Legend Biotech’s IND for LB2501, an investigational single-infusion in vivo CAR-T therapy designed to generate dual CD19/CD20-targeting T cells inside the patient. Legend describes it as the first known dual-targeting in vivo…
Nurix Therapeutics discontinued further clinical development of NX-2127, or zelebrudomide, a dual BTK and IKZF1/3 degrader for B-cell malignancies. Patients already receiving the drug may continue while clinically appropriate, with essential safety monitoring and…
Nava Therapeutics disclosed $89 million in financing to advance a precision lipid-nanoparticle platform designed to deliver RNA beyond the liver, including to immune cells and kidney tissue. The company is developing in vivo CAR-T…
InnoCare presented more than 40 orelabrutinib studies at EHA 2026, including the first treatment-naive CLL/SLL clinical data from US and European patients.
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
